Mouse models of multiple myeloma: technologic platforms and perspectives

Marco Rossi, Cirino Botta, Mariamena Arbitrio, Rosa Daniela Grembiale, Pierosandro Tagliaferri and Pierfrancesco Tassone _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:20119-20133. https://doi.org/10.18632/oncotarget.24614

Metrics: PDF 3035 views  |   HTML 4181 views  |   ?  


Marco Rossi1, Cirino Botta1, Mariamena Arbitrio1, Rosa Daniela Grembiale2, Pierosandro Tagliaferri1 and Pierfrancesco Tassone1,3

1Department of Experimental and Clinical Medicine, “Magna Graecia” University of Catanzaro, Catanzaro, Italy

2Department of Health Sciences, Magna Graecia University, Catanzaro, Italy

3Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Correspondence to:

Pierfrancesco Tassone, email: [email protected]

Keywords: mouse models; multiple myeloma; SCID; SCID-hu; SCID-synth-hu

Received: October 12, 2017    Accepted: February 24, 2018    Published: April 13, 2018


Murine models of human multiple myeloma (MM) are key tools for the study of disease biology as well as for investigation and selection of novel candidate therapeutics for clinical translation. In the last years, a variety of pre-clinical models have been generated to recapitulate a wide spectrum of biological features of MM. These systems range from spontaneous or transgenic models of murine MM, to subcutaneous or orthothopic xenografts of human MM cell lines in immune compromised animals, to platform allowing the engraftment of primary/bone marrow-dependent MM cells within a human bone marrow milieu to fully recapitulate human disease. Selecting the right model for specific pre-clinical research is essential for the successful completion of investigation. We here review recent and most known pre-clinical murine, transgenic and humanized models of MM, focusing on major advantages and/or weaknesses in the light of different research aims.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24614